atTRACTION Success story - BrachyDose: making radiotherapy safer for every patient.

How BrachyDOSE’s radiation dose monitoring technology is transforming cancer care

BrachyDOSE is transforming radiotherapy by providing accurate insight into actual radiation doses, helping reduce — and in some cases eliminate — treatment-related side effects and radiation-caused injuries. Founded in Lithuania in 2024, the startup combines innovative sensor technology with machine learning to enable truly personalised and safer cancer care.

By addressing one of the most persistent challenges in cancer treatment, BrachyDOSE is working to significantly improve the quality and safety of radiotherapy. As founder and CEO Neringa Šeperienė explains, “In certain cases, our technology may help completely eliminate radiotherapy-induced side effects.”
The company’s mission is to equip hospitals with precise, real-time insight into delivered radiation doses, supporting personalised treatment planning and clinical decision-making.

Founded by CEO Neringa Šeperienė and CTO Rimas Šeperys, the company has developed a small, flexible sensor placed near the tumour during treatment. After the procedure, the sensor is scanned, and a machine-learning algorithm analyses discrepancies between prescribed and delivered doses, helping clinicians identify potential tissue damage and reduce harmful side effects. A key advantage of the technology is its compatibility with standard radiotherapy equipment, enabling hospitals to adopt the system without major infrastructure changes.

BrachyDOSE benefitted from the atTRACTION project’s open innovation programme, collaborating with the Kaunas University of Technology Physics Department on coloured radiation exposure indicators. Together, scientists and engineers are developing sensitive, flexible radiation detectors suitable for dual-use applications, including military uniforms for immediate contamination alerts.
As Šeperienė notes, “Through the atTRACTION project, we shared ideas with the Kaunas University of Technology Physics Department on how to create a flexible, reliable detector to inform services such as the military about dangerous ionising radiation exposure. The ‘colored radiation exposure indicators’ initiative has significantly strengthened our academic partnerships.”

The company is collaborating with major healthcare institutions, including the National Cancer Centre at Santaros Clinics, the Oncology Hospital of the Lithuanian University of Health Sciences, and Klaipėda University Hospital, where its technology is undergoing clinical validation. BrachyDOSE has filed a European patent, developed a working prototype, and received support from the European Commission’s Ready2Scale programme.

The startup has actively engaged in atTRACTION-supported events, including the Digital Health & Wellbeing TechMeeting in Paris and the First Customer Acceleration Programme. With support from Tech Park Kaunas, BrachyDOSE also participated in major regional and European events such as Life Sciences Baltics, Startup Fair, Tech Chill, Tartu sTARTUp Day, Latitude59, LOGIN, and sector-specific digital health activities.

BrachyDOSE’s progress is backed by strong investor confidence. The company secured a €554,000 seed investment from Coinvest Capital, BSV Ventures, LitBAN, EstBAN, and a Latvian investor. The funding supports device development, hospital testing, and CE/MDR certification — essential steps toward market deployment.

Today, the BrachyDOSE team brings together expertise in medical device engineering, medical physics, data analytics, and clinical oncology, united by a clear mission: to improve the precision, safety, and effectiveness of radiotherapy and enhance the quality of life for cancer patients worldwide.